Common Contracts
2 similar Underwriting Agreement contracts by Ayala Pharmaceuticals, Inc., Cyclo Therapeutics, Inc.
CYCLO THERAPEUTICS, INC. [●] Shares of Common Stock Pre-Funded Warrants to Purchase up to [●] Shares of Common Stock Warrants to Purchase up to [●] Shares of Common Stock UNDERWRITING AGREEMENTUnderwriting Agreement • November 21st, 2022 • Cyclo Therapeutics, Inc. • Industrial organic chemicals
Cyclo Therapeutics, Inc., a Nevada corporation (the “Company”), proposes, subject to the terms and conditions contained in this Underwriting Agreement (the “Agreement”), to sell to you (the “Underwriter”), an aggregate of (i) [●] shares (the “Shares”) of the Company’s common stock, $0.0001 par value per share (the “Common Stock”), (ii) pre-funded warrants (the “Pre-Funded Warrants”) to purchase up to an aggregate of [●] shares of Common Stock (the “Pre-Funded Warrant Shares”) and (iii) warrants (the “Common Warrants”) to purchase up to an aggregate of [●] shares of Common Stock (the “Common Warrant Shares”). The Shares, the Pre-Funded Warrants, the Pre-Funded Warrant Shares, the Common Warrants and the Common Warrant Shares are collectively referred to as the “Securities.” The Pre-Funded Warrant Shares and the Common Warrant Shares are collectively referred to as the “Warrant Shares.”
AYALA PHARMACEUTICALS, INC. [●] Shares of Common Stock [●] Pre-Funded Warrants [●] Warrants UNDERWRITING AGREEMENTUnderwriting Agreement • July 18th, 2022 • Ayala Pharmaceuticals, Inc. • Biological products, (no disgnostic substances) • New York
Ayala Pharmaceuticals, Inc., a Delaware corporation (the “Company”), proposes, subject to the terms and conditions contained herein, to sell to you and the other underwriters (the “Underwriters”) named on Schedule I to this Underwriting Agreement (the “Agreement”), for whom you are acting as Representative (the “Representative”), an aggregate of (i) [●] shares (the “Shares”) of the Company’s common stock, $0.01 par value per share (the “Common Stock”), (ii) pre-funded warrants to purchase up to [●] shares of Common Stock at an exercise price of $0.01 per share, in the form attached hereto as Exhibit A (the “Pre-Funded Warrants”), and (iii) warrants to purchase up to [●] shares of Common Stock, in the form attached hereto as Exhibit B (the “Common Warrants” and, together with the Pre-Funded Warrants, the “Warrants”). The respective amounts of the Shares, Pre-Funded Warrants and Common Warrants to be purchased by each of the several Underwriters are set forth opposite their names on Sche
